solute carrier family 49 member 3Genealiases: LP2561 · MFSD7
Q-omics provides the consensus-scored SLC49A3 profile across patient tissues and cancer cell-line models. SLC49A3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SLC49A3 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, SLC49A3 RNA expression shows 20,391 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, LUSC, and LSCC as cancer lineages where SLC49A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC49A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC49A3 survival associations across molecular data types. SLC49A3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC49A3 RNA expression–survival associations across cancer types. High SLC49A3 expression shows unfavorable associations in LGG, MESO, LUSC and ACC, but favorable associations in HNSC and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SLC49A3 RNA expression.
This table summarizes SLC49A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC49A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC49A3 shows lower tumor expression in LUSC, COAD, LUAD and READ and higher tumor expression in BRCA and KICH. The LUSC box plot shows higher SLC49A3 RNA expression in normal versus tumor tissue (log2 FC = −1.591, t-test p < 0.001).
This table shows molecular features associated with SLC49A3 in patient tissues and cancer cell lines. In patient samples, SLC49A3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC49A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
